4//SEC Filing
Rich Stuart 4
Accession 0001654954-25-005950
CIK 0000034956other
Filed
May 19, 8:00 PM ET
Accepted
May 20, 6:54 PM ET
Size
14.4 KB
Accession
0001654954-25-005950
Insider Transaction Report
Form 4
Rich Stuart
DirectorChief Medical Officer
Transactions
- Award
Stock Option (right to buy)
2025-05-16+625,000→ 625,000 totalExercise: $5.89Exp: 2034-05-16→ Common Stock (625,000 underlying)
Holdings
- 266
Common Stock
- 1,194(indirect: By Trust)
Common Stock
- 63
Stock Option (right to buy)
Exercise: $992.00Exp: 2032-06-09→ Common Stock (63 underlying) - 119
Stock Option (right to buy)
Exercise: $3.55Exp: 2034-05-17→ Common Stock (119 underlying) - 1,194(indirect: By Trust)
Common Stock
- 157
Stock Option (right to buy)
Exercise: $2848.00Exp: 2031-01-15→ Common Stock (157 underlying) - 500,000
Stock Option (right to buy)
Exercise: $5.94From: 2025-12-10Exp: 2034-12-10→ Common Stock (500,000 underlying)
Footnotes (6)
- [F1]The Reporting Person is special asset advisor to the Stuart Rich 2022 Irrevocable Trust, a Spousal Lifetime Access Trust (the "Trust"). As such, the Reporting Person has voting and dispositive power over the reported securities held in the Trust, however disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.
- [F2]The Reporting Person is co-trustee of the Andrea Rich 2021 Irrevocable Trust and disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.
- [F3]The options vest and become exercisable as follows: 25% of the underlying shares of common stock vest and become exercisable on May 16, 2026, and thereafter 1/36th of the remaining shares will vest on the last day of each following month for a period of 36 months, subject to the Reporting Person's continued employment.
- [F4]The options vest and become exercisable in four equal installments, with 25% vesting after the start of a Phase 3 clinical trial, 25% vesting after the database lock with respect to the trial, 25% vesting after the opening of an Investigational New Drug Application with the U.S. Food and Drug Administration ("FDA"), and 25% vesting after the approval from the FDA, subject to the Reporting Person's continued employment.
- [F5]The options vest and become exercisable as follows: 25% of the underlying shares of common stock vest and become exercisable on each of June 9, 2023, June 9, 2024, June 9, 2025, and June 9, 2026, subject to the Reporting Person's continued employment.
- [F6]The options vest and become exercisable as follows: 25% of the underlying shares of common stock vest and become exercisable on each of May 17, 2025, May 17, 2026, May 17, 2027 and May 17, 2028, subject to the Reporting Person's continued employment.
Documents
Issuer
TENAX THERAPEUTICS, INC.
CIK 0000034956
Entity typeother
Related Parties
1- filerCIK 0001841785
Filing Metadata
- Form type
- 4
- Filed
- May 19, 8:00 PM ET
- Accepted
- May 20, 6:54 PM ET
- Size
- 14.4 KB